Advances both major and microscopic
AN ISRAELI treatment t o promote the healing of chronic wounds is now a v a i l a b l e i n London at the newly opened London Wound Clinic i n Harley Street. The clinic specialises in the treatment and management of chronic wounds, such as leg and foot ulcers or pressure sores. Foot ulcers occur in 15 per cent of diabetic patients, owing to the associated loss of sensation in the lower limbs, while pressure sores affect up to 20 per cent of hospital inpatients.
This is the first specialist clinic in the UK to offer the Israeli BRH therapy, which uses a combination of electrostimulation and l o w- f r e q u e n c y ultrasound. The LondonWound Clinic and surgeon Jeremy Crane painless, non-invasive technology aids healing by increasing blood flow within wounds. On the team at the London Wound Clinic are Jeremy Crane, consultant vascular and transplant surgeon (Imperial College Healthcare NHS Trust); Lynne Hudgell, senior lecturer in tissue viability; and Dr Miles Boyden, GP.
Tina Chambers, vice chair of the Tissue Viability Society, says: “An open wound on the foot or leg can lead to infection, which can at best cause delay in healing and at worst result in amputation and death. With the number of diabetic patients increasing, the number of people with foot ulceration will grow, increasing the burden on the health service. Any technology that can assist in the healing of these chronic wounds and thereby decrease the numbers requiring treatment will be beneficial, not only to the patient themselves, but the healthcare system too. “The BRH-A2 therapy combines two known t e c h n o l o g i e s i n wound care, and early signs are that it can help some diabetic foot wounds and leg ulcers heal faster.
“This is bene f i c i a l , a s t h e quicker the wound closes, the speedier the reduction in the associated risk of
Centrasight’s minuscule telescope restores central vision
HELP IN SIGHT
Age-related macular degeneration (AMD) is the most common cause of blindness in people aged 60 and over in the UK, experienced by more than 600,000 people. It affects the central vision which we use to recognise faces and see objects in front of us.
Until the recent development of a treatment called CentraSight, there were few options for people with endstage AMD. Spire Bushey Hospital’s ophthalmic unit is the latest centre in the UK to offer CentraSight to those with AMD. The treatment uses a tiny telescope implant, smaller than a pea, which magnifies images about three times. The enlarged images are projected on to the healthy part of the retina, making it possible to use the central vision again.
The procedure is painless and takes